title: Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.
abstract: The role of nucleoside analogues (NAs) in lipodystrophy (LD) syndrome in human immunodeficiency virus (HIV)-infected patients remains controversial. We studied the prevalence of LD in previously untreated patients randomized to receive different NA combinations (in the ALBI-ANRS 070 trial) for 6 months. At month 30 of follow-up, 37 (31%) of 120 patients had >/=1 morphologic change, and 21 (57%) of 37 had isolated peripheral lipoatrophy; corresponding values for the patients who received only NAs throughout follow-up were 20 (30%) of 66 and 14 (67%) of 21, respectively. In multivariate analysis, factors associated with presence of LD at month 30 were initial assignment to the group receiving stavudine and didanosine (odds ratio [OR], 6.7; P=.02), age (OR for being 10 years older, 3.6; P=.002), and HIV RNA level at month 30 (OR, 0.4; P=.007). No difference was observed in cholesterol and glucose levels as a function of any pattern of antiretroviral exposure. Exposure to stavudine and didanosine was associated with LD syndrome (predominantly lipoatrophy).
authors.affiliation: INSERM Unité 330, Université Victor Segalen Bordeaux 2, 33076 Bordeaux Cédex, France. genevieve.chene@isped.u-bordeaux2.fr
authors.forename: Geneviève
authors.initials: G
authors.lastname: Chêne
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Angelini
authors.forename: Laurent
authors.initials: L
authors.lastname: Cotte
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Lang
authors.forename: Philippe
authors.initials: P
authors.lastname: Morlat
authors.forename: Corinne
authors.initials: C
authors.lastname: Rancinan
authors.forename: Thierry
authors.initials: T
authors.lastname: May
authors.forename: Valérie
authors.initials: V
authors.lastname: Journot
authors.forename: François
authors.initials: F
authors.lastname: Raffi
authors.forename: Bernard
authors.initials: B
authors.lastname: Jarrousse
authors.forename: Michèle
authors.initials: M
authors.lastname: Grappin
authors.forename: Gérard
authors.initials: G
authors.lastname: Lepeu
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Molina
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced* / Q000209:etiology; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000209:etiology; D015999:Multivariate Analysis; D009705:Nucleosides / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D009705:Nucleosides